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Fragile X syndrome, the most commonly known genetic cause of autism, is due to loss of the 
fragile X mental retardation protein, which regulates signal transduction at metabotropic 
glutamate receptor-5 in the brain. Fragile X mental retardation protein deletion in mice 
enhances metabotropic glutamate receptor-5-dependent long-term depression in the 
hippocampus and cerebellum. Here we show that a distinct type of metabotropic glutamate 
receptor-5-dependent long-term depression at excitatory synapses of the ventral striatum and 
prefrontal cortex, which is mediated by the endocannabinoid 2-arachidonoyl-sn-glycerol, is 
absent in fragile X mental retardation protein-null mice. In these mutants, the macromolecular 
complex that links metabotropic glutamate receptor-5 to the 2-arachidonoyl-sn-glycerol-
producing enzyme, diacylglycerol lipase-α (endocannabinoid signalosome), is disrupted 
and metabotropic glutamate receptor-5-dependent 2-arachidonoyl-sn-glycerol formation 
is compromised. These changes are accompanied by impaired endocannabinoid-dependent 
long-term depression. Pharmacological enhancement of 2-arachidonoyl-sn-glycerol signalling 
normalizes this synaptic defect and corrects behavioural abnormalities in fragile X mental 
retardation protein-deficient mice. The results identify the endocannabinoid signalosome as a 
molecular substrate for fragile X syndrome, which might be targeted by therapy. 
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Fragile X syndrome (FRAX), the most frequently known genetic cause of autism, is characterized by a series of physical, cogni-tive and emotional symptoms that include social deficits and 
diminished ability to learn1. FRAX is due to the mutation of a single 
gene, called FMR1 (ref. 2), which encodes for the fragile X mental 
retardation protein (FMRP)3. FMRP regulates the translation and 
transport of messenger RNAs in dendritic spines of brain neurons, 
and is involved in modulating signal transduction through type-I 
metabotropic glutamate (mGlu1 and mGlu5) receptors at glutama-
tergic synapses throughout the brain. Loss of FMRP causes pro-
found changes in the structure of neuronal dendrites and enhances, 
in the hippocampus and cerebellum of FMRP-deficient (fmr1 − / − ) 
mice, a form of long-term depression (LTD) that requires mGlu5 
receptor-mediated protein synthesis3–7.
In medium spiny neurons of the ventral striatum and pyramidal 
neurons of the prefrontal cortex (PFC), activation of mGlu5 receptors 
initiates a distinct form of LTD, which does not depend on protein 
synthesis and is affected by the retrograde endocannabinoid (eCB) 
transmitter, 2-arachidonoyl-sn-glycerol (2-AG)8,9. Stimulation of 
mGlu5 receptors releases 2-AG through the sequential recruitment 
of two enzymes: phospholipase C-β, which produces 1,2-diacyl-sn- 
glycerol, and diacylglycerol lipase-α (DGL-α), which converts 
1,2-diacyl-sn-glycerol into 2-AG10–12. Morphological studies have 
shown that both phospholipase C-β and DGL-α are localized to the 
perisynapse, a subdivision of the dendritic spine that forms a 100–
200-nm-thick border around the postsynaptic density13. mGlu5 
receptors are concentrated in this region14 where they may be physi-
cally linked to DGL-α through the adaptor protein Homer10,15. This 
supramolecular complex is likely to have an important role in eCB-
mediated transmission at excitatory synapses, by providing a focal 
point for the generation of a 2-AG pool that is specifically commit-
ted to retrograde transmission. The 2-AG produced by this complex 
can readily cross the synaptic cleft to access CB1 cannabinoid recep-
tors on presynaptic terminals, where the 2-AG-deactivating enzyme 
monoacylglycerol lipase (MGL) is also found16,17. We propose that 
this complex, which we refer to as ‘eCB signalosome’, allows for the 
separation of the 2-AG pool responsible for eCB signalling from 
other cellular pools of 2-AG, such as those involved in eicosanoid 
production and phospholipid remodelling.
FMRP deletion is known to be associated with greater eCB-
mediated responses at GABAergic synapses of the dorsal striatum 
and CA1 region of the hippocampus18,19. Here, we show that loss 
of FMRP is accompanied by marked deficits in mGlu5-dependent 
2-AG release and eCB-mediated LTD at excitatory synapses of the 
forebrain, as well as by a structural disorganization in the eCB signa-
losome. We further show that inhibition of presynaptic MGL activ-
ity normalizes eCB-mediated LTD and corrects key behavioural 
abnormalities in fmr1 − / −  mice, suggesting that pharmacological 
enhancement of 2-AG signalling might offer a new therapeutic 
strategy for FRAX.
Results
FMRP binds DGL- mRNA and controls 2-AG signalling. FMRP 
regulates protein translation in postsynaptic spines by interacting 
with mRNAs that often, albeit not always, contain a G-quartet 
FMRP-binding motif 20. A bioinformatics search showed that an 
FMRP-binding sequence is present in DGL-α mRNA (Fig. 1a), 
but not in mRNAs encoding for structurally or functionally related 
enzymes such as DGL-β, MGL, N-acylphosphatidylethanolamine-
selective phospholipase D (NAPE-PLD) and α/β hydrolase 
domain-6 (ABHD6) (data not shown). To test whether FMRP 
binds the DGL-α message, we immunoprecipitated FMRP from 
mouse forebrain homogenates and used quantitative PCR to 
measure DGL-α mRNA in the pellets. The pellets contained DGL-α 
mRNA (Fig. 1b), but no detectable levels of mRNAs encoding 
for DGL-β or NAPE-PLD (Fig. 1c). As expected, the precipitates 
also contained mRNAs encoding for PSD-95 and amyloid 
precursor protein, which are known to bind FMRP21,22 (Fig. 1d). 
Moreover, experiments with rat cortical neurons in primary 
cultures showed that exposure to the mixed mGlu1/mGlu5 receptor 
agonist (S)-3,5-dihydroxyphenylglycine (DHPG) (100 µM) caused 
the dissociation between FMRP and DGL-α mRNA (Fig. 1e), as 
previously shown for other FMRP-regulated messages22.
To examine whether FMRP deletion influences mGlu5-dependent 
2-AG signalling, we used mouse brain synaptoneurosomes, a 
subcellular preparation enriched in resealed postsynaptic spines 
attached to their corresponding axon terminals23. As expected 
for previous results10,11, incubation of wild-type synaptone-
urosomes with DHPG resulted in a rapid increase in DGL activ-
ity, which was dependent on both incubation time and DHPG 
concentration (Fig. 2a,b), and was accompanied by an elevation 
in 2-AG levels (Fig. 2c). These effects were not associated with 
changes in DGL-α content (Fig. 2d) and were not prevented by 
the translation inhibitor cycloheximide (Supplementary Fig. S1A), 
indicating that they did not require the synthesis of new DGL-α  
protein. In synaptoneurosomes prepared from fmr1 − / −  mice, 
DHPG failed to stimulate DGL activity and 2-AG production 
(Fig. 2a–c), even though baseline levels of 2-AG were similar to 
those measured in wild-type controls (Supplementary Fig. S1B). The 
results suggest that genetic loss of FMRP disrupts mGlu5-dependent 
2-AG signalling at excitatory synapses.
FMRP targets DGL- to the perisynapse. One mechanism 
through which FMRP deletion might affect receptor-operated 2-AG 
production is by altering the structure of the supramolecular com-
plex that couples mGlu5 receptors to DGL-α (which we refer to here 
as ‘eCB signalosome’). To test this possibility, we immunostained 
for mGlu5 or DGL-α brain sections from wild-type and fmr1 − / −  
mice. We first focused on the core of the ventral striatum, a brain 
region in which the eCB system mediates excitatory LTD8. Immu-
noperoxidase labelling for mGlu5 or DGL-α revealed a dense 
punctuate distribution throughout the neuropil, which appeared 
to be similar between wild-type and fmr1 − / −  mice (Fig. 3a,b,g,h). 
Further analyses by immunogold electron microscopy revealed 
a widespread presence of mGlu5 and DGL-α in postsynaptic 
profiles—predominantly in dendritic spine heads that received 
asymmetric, putatively glutamatergic inputs from DGL-α or mGlu5-
immunonegative axon terminals (Fig. 3c,d,i,j). To assess whether 
FMRP deletion alters the subcellular distribution of mGlu5 and 
DGL-α, in three separate experiments we measured the distance 
along the plasma membrane between the gold particles attached 
to DGL-α or mGlu5 and the closest edge of the postsynaptic 
density. There was no statistically detectable difference in the 
subcellular distribution of mGlu5 between wild-type and fmr1 − / −  
mice (n = 294 and 285 synapses for wild-type and fmr1 − / −  mice, 
respectively; Kolmogorov–Smirnov test, P = 0.917) (Fig. 3k). By 
contrast, the cumulative distribution functions of the subcellular 
localization of DGL-α were significantly different between the two 
genotypes (n = 259 and 185 synapses for wild-type and fmr1 − / −  
mice, respectively; P = 0.001) (Fig. 3e). This suggests that FMRP 
deletion selectively impairs the subcellular targeting of DGL-α  
in postsynaptic spine heads, without affecting the targeting 
of mGlu5.
To investigate this phenomenon further, we divided the spine-
head plasma membrane into 60-nm bins and calculated the fre-
quency of gold particles within each bin. As previously shown for 
the hippocampus13, particles associated with DGL-α were con-
centrated in the perisynaptic zone, with a gradient that decreased 
towards the spine neck, and were nearly absent from the intrasynap-
tic domain (Fig. 3f). This skewed distribution was clearly detectable 
in the ventral striatum core of wild-type mice, but was totally absent 
in fmr1 − / −  mutants (Fig. 3f). Swapping all data points in the first 
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60-nm bin of wild-type mice to the same data set of fmr1 − / −  ani-
mals and vice versa eliminated statistical significance (Kolmogorov–
Smirnov test, P = 0.187 and P = 0.332 for wild-type to fmr1 − / −  swap 
and fmr1 − / −  to wild-type swap, respectively). As swapping data sets 
in other bins did not reveal differences, the disappearance of DGL-α 
labelling from the perisynaptic domain may underlie the difference 
in the cumulative distribution functions. Furthermore, the same 
analytical approach revealed a biased perisynaptic localization of 
mGlu5 in both wild-type and fmr1 − / −  mice (Fig. 3l).
To determine whether FMRP deletion influences the subcellu-
lar targeting of DGL-α in other forebrain structures, we examined 
the localization of mGlu5 and DGL-α in the CA1 subfield of the 
hippocampal formation,9,13,24,25. The perisynaptic localization of 
mGlu5 at hippocampal excitatory synapses was identical between 
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Figure 1 | DGL- mRNA binds to FMRP. (a) Alignment of the coding region in human (h), mouse (m) and rat (r). DGL-α mRnAs reveal a putative 
G-quartet sequence within a G-rich region containing several DWGG repeats. The canonical G-quartet motif is DWGG-n(0–5)-DWGG-n(0–3)-DWGG-
n(0–2)-DWGG, where D is any nucleotide except C, and W is A or u. The DWGG repeats are boxed in red. (b) Co-immunoprecipitation of FmRP with 
DGL-α mRnA. Brains from wild-type or fmr1 − / −  mice were homogenized and centrifuged at 70,000 g for 30 min. The supernatant (1 mg protein) was 
incubated with the indicated amounts of anti-FmRP antibody or normal serum (ns), and the immunocomplex was precipitated using protein G-sepharose 
beads. Top, levels of DGL-α mRnA in the immunoprecipitates were quantified by real-time quantitative PCR (n = 3, ***P < 0.001). Bottom, a portion of 
the immunoprecipitate was subjected to sDs–PAGE and western blot analyses to confirm the presence of FmRP. (c,d) Analyses of mRnAs encoding for 
DGL-α, DGL-β and nAPE-PLD (c) or positive control PsD-95 and amyloid precursor protein (d) in anti-FmRP-immunoprecipitates (n = 3, **P < 0.01 and 
***P < 0.001 compared with ns, ##P < 0.01 and ###P < 0.001 compared with DGL-α-anti-FmRP). similar results were obtained using fmr1 − / −  mice bred 
on either a FVB.129 background (b,c) or a C57BL/6J background (d). (e) DHPG-induced dissociation of DGL-α mRnA from FmRP in cultured cortical 
neurons. Rat primary neurons were prepared from embryonic day 18 cortex, as described55. Cells were treated with DHPG (100 µm) in culture medium 
and harvested at the indicated time. Levels of FmRP-bound DGL-α mRnA were determined by anti-FmRP immunoprecipitation and quantitative PCR,  
as described in methods (n = 5, ***P < 0.001). Results are representative of at least two independent experiments. significance was determined using  
two-tailed student’s t-test. Error bars represent s.e.m.
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fmr1 − / −  and wild-type mice, whereas the localization of DGL-α  
was markedly impaired in fmr1 − / −  mutants (Supplementary 
Fig. S2). An economical interpretation of these findings, which is 
consistent with our biochemical data, is that FMRP enables the 
correct targeting of DGL-α and its assembly with mGlu5 into a 
functional eCB signalosome at excitatory synapses throughout the 
forebrain.
FMRP is a core component of the translational machinery 
in dendritic polyribosomes and has been implicated in the 
transport and localization of mRNAs to dendrites and synapses3. 
We reasoned therefore that, in the absence of FMRP, DGL-α mRNA 
might be translated ectopically. Consistent with this prediction, an 
analysis of 300 synapses per genotype revealed an increased aver-
age density of intracellular DGL-α labelling in the ventral striatum 
of fmr1 − / −  mice, compared with wild-type animals (0.91 (range: 
0.6–1.43) gold particles per µm2 and 3.02 (range: 2.19–3.63) gold 
particles per µm2 in wild-type and fmr1 − / −  animals, respectively, 
normalized to background levels) (Fig. 3m). This increase in nor-
malized average density was also reflected in the ratio of intracel-
lularly localized DGL-α (14% (range: 10–17%) and 36% (range: 
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Figure 2 | mGlu5 receptor-stimulated DGL activity and 2-AG release is disrupted in fmr1 − / −  mice. (a) synaptoneurosome (sn) fractions prepared 
from wild-type or fmr1 − / −  mice (1 mg ml − 1) were incubated at 37 °C for 30 min in the presence of 100 µm DHPG, and DGL activity was measured in vitro 
using 10 µm diheptadecanoylglycerol as a substrate (n = 4). (b) DGL activity was measured in sn fractions after incubation with various concentrations 
of DHPG (n = 3). (c) 2-AG levels in sn fractions were measured after 45-min incubation with DHPG (100 µm) or vehicle (Veh, PBs) (n = 5–9). (d). After 
treatment of synaptoneurosomes with DHPG, as described above, levels of DGL-α protein were measured by western blot. Representative images for 
DGL-α and loading control actin are shown (n = 6 each). Experiments were conducted on fmr1 − / −  mice on C57BL/6J (a,d) or FVB.129 background (b,c). 
Results are representative of at least two independent experiments. significance was determined using two-tailed student’s t-test. *P < 0.05, **P < 0.01 
and ***P < 0.001. Error bars represent s.e.m.
Figure 3 | Impaired targeting of DGL- to the perisynaptic domain of excitatory synapses in fmr1 − / −  mice. DGL-α immunoperoxidase labelling in wild-
type (a) and fmr1 − / −  mice (b) reveals a similar granular staining pattern in the neuropil of the accumbens/ventral striatum (arrowheads). medium spiny 
neuron somata are devoid of labelling (asterisks). aco, anterior commissure. Electron micrographs of asymmetric synapses reveal that DGL-α-positive 
gold particles (arrowheads) are predominantly found perisynaptically, close to the PsD (red arrows) in wild-type animals (c), but not in fmr1 − / −  synapses 
(d) s, spine head; b, bouton. (e) Cumulative distribution plot of DGL-α localization in wild-type (solid line, n = 259) and fmr1 − / −  spines (dashed line, 
n = 185). (f) Histogram summarizing the normalized distribution of DGL-α-immunogold on the spine head membrane of wild-type mice (black arrow and 
black bars, n = 259) and fmr1 − / −  mice (grey arrow and grey bars, n = 185). Large arrow  =  edge of PsD. mGlu5 immunoperoxidase labelling in wild-type 
(g) and fmr1 − / −  animals (h) depicts a similar granular labelling pattern (arrowheads) as DGL-α. Electron micrographs of asymmetric synapses containing 
mGlu5-immunogold labelling (arrowhead) revealed that mGlu5 was predominantly found perisynaptically (red arrows) in both wild-type (i) and fmr1 − / −  
spines (j). (k) Cumulative distribution plot of mGlu5-immunogold localization in wild-type (solid line, n = 294) and fmr1 − / −  mice (dashed line, n = 285).  
(l) Histogram representing the normalized distribution of mGlu5-immunogold on spine heads of wild-type (black arrow and black bars, n = 294) and 
fmr1 − / −  spines (grey arrow and grey bars, n = 285). The number of DGL-α-positive spines was higher in fmr1 − / −  mice; however, the density of spine head 
membrane labelling was the same in both strains. Instead, a significantly higher density of DGL-α labelling was found within the spine head and neck 
cytoplasm (arrowheads; m1–m2) and along the spine neck membrane (black arrowheads; n). symmetrical synapses are considered inhibitory GABAergic 
inputs and frequently synapse onto spine necks (red arrowhead; n) and dendritic shafts Importantly, the number of DGL-α positive symmetrical synapses 
were similar in wild-type (o) and fmr1 − / −  mice (p). scale bars: 15 µm in a,b,g and h and 100 nm in c,d,i,j,m–p.
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33–46%) of all gold particles found in dendritic spine heads in wild-
type and fmr1 − / −  animals, respectively). In another experiment, we 
assessed the presence of DGL-α labelling in a second data set of 
75 random intact spines per animal. We found that fmr1 − / −  spines 
had a higher probability of DGL-α labelling than did wild-type 
spines (χ2 test, P <  0.001).
In which subcellular structure was DGL-α labelling concentrated? 
To address this question, we divided each spine into three distinct 
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compartments: spine-head membrane, spine-neck membrane, and 
head and neck cytoplasm. The number of DGL-α gold particles on 
the spine head membrane was very similar between wild-type and 
fmr1 − / −  mice (χ2 test, P = 0.696). By contrast, we found a signifi-
cantly higher number of DGL-α gold particles in spine neck mem-
brane (χ2 test, P < 0.001) (Fig. 3n) and cytoplasm (χ2 test, P = 0.003) 
of fmr1 − / −  mice. In agreement with previous studies26,27, we found 
that dendrites in fmr1 − / −  mice exhibited longer spine necks than 
wild-type (852 ± 19 and 1030 ± 24 nm in wild-type and fmr1 − / −  
respectively; Kolmogrov–Smirnov test, P < 0.001), which might 
account for the higher number of DGL-α gold particles observed 
in these animals. However, when we calculated the density of 
DGL-α labelling for each spine compartment, this was also signifi-
cantly higher in the fmr1 − / −  necks than wild-type mice (2.29 (range: 
1.63–3.01) gold particles per µm2 and 4.67 (range: 3.63–5.85) gold 
particles per µm2 in wild-type and fmr1 − / −  animals, respectively). 
By contrast, the density of DGL-α labelling in the spine-head 
membrane was similar between the two strains (1.26 (range: 
0.43–1.89) gold particles per µm2 and 1.42 (range: 1.06–1.86) gold 
particles per µm2 in wild-type and fmr1 − / −  animals, respectively), 
but higher intracellular labelling was observed in fmr1 − / −  mice 
(0.4 (range: 0.2–0.8) gold particles per µm2 and 0.91 (range: 0.78–
0.92) gold particles per µm2 in wild-type and fmr1 − / −  animals, 
respectively).
Finally, we examined whether FMRP deletion might affect 
DGL-α localization at GABAergic synapses, which are also dys-
functional in fmr1 − / −  mice18,19. DGL-α gold particles were found 
at the postsynaptic plasma membrane of both wild-type (Fig. 3o) 
and fmr1 − / −  mice (Fig. 3p), but no statistically detectable difference 
was noted in their distribution (χ2 test, P = 0.6, n = 150). The results 
suggest that genetic FMRP deletion alters the normal localization of 
DGL-α at excitatory, but not inhibitory, synapses of the forebrain, 
causing this enzyme to accumulate ectopically in the neck and 
cytoplasm of dendritic spines.
FMRP enables eCB-LTD in ventral striatum and PFC. The bio-
chemical and ultrastructural results reported above suggest that 
FMRP deletion reduces 2-AG-dependent LTD at excitatory synapses 
of the forebrain. In acutely dissected brain slices from wild-type 
mice, low-frequency electrical stimulations (10 min, 10 Hz) elic-
ited robust LTD of excitatory postsynaptic currents (EPSCs, Fig. 4a, 
white symbols) or extracellular field potentials (fEPSP, see Fig. 5a) in 
medium spiny neurons of the ventral striatum8. The induction of LTD 
was prevented by the DGL-α inhibitor tetrahydrolipstatin (10 µM) 
(Fig. 4b), as expected from previous work9,28, and was not affected 
by pharmacological blockade of protein synthesis (Supplementary 
Fig. S3). Importantly, the same low-frequency stimulations that caused 
LTD in wild-type mice failed to do so in fmr1 − / −  mutants (Figs 4a 
and 5a, black symbols). Moreover, bath applications of the mixed 
mGlu1/mGlu5 agonist, DHPG, which consistently elicited LTD in 
brain slices prepared from wild-type mice, were ineffective in slices 
obtained from fmr1 − / −  mutants (Fig. 4c). To evaluate whether the 
deficits in eCB-LTD observed in fmr1 − / −  mutants extended beyond 
the ventral striatum, we took advantage of the fact that this brain 
region receives major excitatory projections from the medial PFC, 
a structure where mGlu5 activation also underlies 2-AG-dependent 
eCB-LTD at synapses of pyramidal neuron layers 2/3 and 5/6 
(refs 9,29). Similar to the ventral striatum, eCB-LTD was absent in 
PFC slices obtained from fmr1 − / −  mutants (Fig. 4d). Together, these 
results support the idea that FMRP deletion causes a widespread 
impairment of mGlu5-dependent LTD at excitatory synapses.
To test the alternative possibility that the LTD deficit observed in 
fmr1 − / −  mice might result from impaired CB1 receptor function, 
we assessed the ability of the cannabinoid agonist CP55940 (0.01–
10 µM) to inhibit synaptic transmission in slices of ventral striatum 
prepared from wild-type or fmr1 − / −  mice. The drug’s potency and 
efficacy were identical in the two strains (Supplementary Fig. S4A), 
indicating that CB1 receptors function normally in fmr1 − / −  mice. 
Moreover, tonic eCB signalling did not appear to be affected by 
FMRP deletion, because the selective CB1 inverse agonist AM251 
(4 µM, applied 30 min before testing) did not alter baseline excita-
tory transmission in the ventral striatum of wild-type or fmr1 − / −  
mice (Supplementary Fig. S4B). Thus, the lack of eCB-dependent 
plasticity observed in fmr1 − / −  mice cannot be accounted for by 
alterations in CB1 function or tonic eCB activity. We also compared 
the intrinsic properties of ventral striatum medium spiny neurons 
in wild-type and fmr1 − / −  mice, and found no difference in medium 
spiny neurons excitability (Supplementary Fig. S5). Deletion of 
FMRP may negatively impact the basic properties of ventral stria-
tum excitatory synapses and, to test for this possibility, we recorded 
AMPA receptor-mediated spontaneous EPSCs (sEPSCs) in medium 
spiny neurons of both genotypes. The amplitude and frequency 
of AMPAR sEPSCs were similar in wild-type and fmr1 − / −  mice 
(Supplementary Fig. S6). The results rule out the possibility that 
modifications of excitability or basal synaptic properties of ventral 
striatum medium spiny neurons may be responsible for impaired 
eCB-LTD in fmr1 − / −  mice.
To test whether FMRP might influence intracellular signal trans-
duction pathways mediating other forms of LTD, we also analysed 
the LTD evoked by presynaptic mGlu2/3 receptors, which utilizes 
the same transduction mechanisms that are engaged by presyn-
aptic CB1 receptors30,31. Bath application of the selective mGlu2/3 
agonist LY379268 (100 nM) produced comparable levels of LTD in 
wild-type and fmr1 − / −  mice (Supplementary Fig. S7). Together, 
our experiments support the conclusion that FMRP enables mGlu5  
to initiate retrograde 2-AG signalling and elicit LTD at excitatory 
synapses of the forebrain.
Enhancement of 2-AG signalling normalizes LTD in fmr1 − / −  
mice. The results reported above suggest that, in fmr1 − / −  mice, the 
failure of DGL-α to associate with mGlu5 into a functional eCB sig-
nalosome results in a loss of eCB-LTD. We have previously shown 
that pharmacological blockade of intracellular 2-AG hydrolysis, 
which is predominantly catalysed by presynaptic MGL16,32, lowers 
the threshold for LTD induction at excitatory synapses of the ven-
tral striatum9,29. We hypothesized therefore that inhibitors of 2-AG 
degradation might normalize LTD in fmr1 − / −  mice by reinforc-
ing 2-AG activity at residual intact synapses or, possibly, extending 
the reach of ectopically produced 2-AG. To test this possibility, we 
blocked 2-AG hydrolysis in slices using the potent and irreversible 
MGL inhibitor, JZL18433. Brain slices were incubated with JZL184 
(1 µM) for 45–90 min before LTD induction. This treatment was 
sufficient to restore both synaptic and pharmacologically induced 
LTD in slices prepared from fmr1 − / −  mutants (Fig. 5a,b), but had 
no effect in slices from wild-type controls (Supplementary Fig. S8). 
In addition, inhibition of the postsynaptic 2-AG-hydrolysing 
enzyme ABHD629 with WWL70 (10 µM, 45–90-min incubation) 
also restored LTD in slices from ventral striatum of fmr1 − / −  mice 
(Fig. 5a,b). The effects of JZL184 and WWL70 indicate that phar-
macological blockade of either presynaptic or postsynaptic 2-AG 
degradation rescues eCB-dependent LTD in fmr1 − / −  mice.
Enhancing 2-AG corrects behavioural changes in fmr1 − / −  mice. 
When bred on a C57BL/6 background, fmr1 − / −  mice display a 
behavioural phenotype that is characterized by elevated motor 
activity in an open field (Fig. 6a,b) and decreased aversion to the 
open arms of an elevated plus maze34 (Fig. 6c,d). The MGL inhibi-
tor JZL184 (16 mg kg − 1, intraperitoneal) increased brain 2-AG 
levels (Supplementary Fig. S9A) and corrected these behavioural 
abnormalities within 6 h of administration (Fig. 6a–d). In fmr1 − / −  
mice, JZL184 reduced the number of squares crossed (Fig. 6a) 
and the total distance travelled (Fig. 6b) in the open field test. 
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The compound also reduced the number of entries and the time 
spent in the open arm in the elevated plus maze test (Fig. 6c,d and 
Supplementary Fig. S9C, D). By contrast, JZL184 did not signifi-
cantly affect open field or elevated plus maze behaviours in wild-type 
mice (Fig. 6a–d and Supplementary Fig. S9B–D). These experiments 
suggest that pharmacological enhancement of 2-AG signalling 
normalizes two key behavioural changes observed in fmr1 − / −  mice.
Discussion
In the present study, we provide three lines of evidence indicating 
that FMRP exerts a tight regulatory control over 2-AG-dependent 
retrograde signalling at excitatory synapses of the mouse forebrain. 
First, we show that an FMRP antibody selectively immunoprecipi-
tates DGL-α mRNA in forebrain synaptoneurosome extracts. This 
is suggestive of a direct association between the two molecules, pos-
sibly through an interaction of FMRP with the G-quartet motif of 
DGL-α mRNA35. Second, we report that the normal perisynaptic 
colocalization of DGL-α and mGlu5 is severely impaired in fmr1 − / −  
mice, indicating that FMRP is necessary for the correct targeting 
of DGL-α to dendritic spines. Finally, we find that FMRP deletion 
disrupts both mGlu5-stimulated 2-AG production in synaptoneu-
rosomes and LTD at excitatory synapses of the ventral striatum and 
PFC. These findings suggest that FMRP may direct the assembling 
of DGL-α and mGlu5 into a functional signalosome, and is essential 
for retrograde 2-AG transmission at glutamatergic synapses (Fig. 7). 
Underscoring the functional significance of these results, we 
show that pharmacological blockade of 2-AG degradation rein-
states eCB-dependent LTD and corrects key behavioural changes in 
fmr1 − / −  mice.
The eCB 2-AG is considered to be a primary effector of mGlu5-
dependent plasticity in the brain9,12,28, but the dynamics of 2-AG 
signalling at central synapses are still unclear. One important ques-
tion pertains to the mechanism through which mGlu5 activation 
stimulates production of the 2-AG pool responsible for retrograde 
eCB transmission. Based on the present results, we hypothesize that 
the stable association of mGlu5 and DGL-α into a multiprotein 
complex at the perisynaptic annulus of the dendritic spine provides 
a structural scaffold that allows for the localized formation of a sig-
nalling-competent pool of 2-AG, which may be distinct from the 
intracellular 2-AG pools involved in phospholipid remodelling and 
eicosanoid biosynthesis36,37. We propose to call this complex ‘eCB 
signalosome’, to signify its pivotal role in eCB-mediated retrograde 
transmission (Fig. 7).
How does the lack of FMRP expression alter the structure of 
the eCB signalosome? The available data suggest two possibilities. 
The first is that, in the absence of FMRP, the DGL-α message may 
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be incorrectly targeted within the dendritic spines, leading to errors 
in the timing of DGL-α translation or the localization of the trans-
lated protein. An error in spatial mRNA delivery caused by FMRP 
deletion was recently demonstrated for another key postsynaptic 
protein, calmodulin-activated protein kinase II38. A second possi-
bility is that FMRP deletion may produce an alteration in the func-
tion of Homer proteins. These scaffolding proteins bind both mGlu5 
and DGL-α10, and single-point mutations in the Homer-2-binding 
region of DGL-α result in an enzyme that retains functional activ-
ity, but is found in intracellular membrane compartments rather 
than the plasma membrane10. Notably, uncoupling of mGlu5 from 
the postsynaptic Homer scaffold results in the absence of mGlu- 
activated retrograde 2-AG signalling at excitatory synapses39. Previ-
ous studies suggest a similar functional uncoupling between mGlu5 
and Homer-2 in fmr1 − / −  mice, despite comparable protein levels 
in synaptoneurosome preparations40. In support of this idea, an 
altered balance in mGlu5 scaffolding between short-form Homer 1a 
and long-form Homer proteins was found in fmr1 − / −  mice41. The 
hypotheses outlined above will be tested in future experiments.
The mGlu receptor theory of FRAX is based on the seminal 
observation that fmr1 − / −  mice display a marked enhancement 
of a form of hippocampal LTD that depends on mGlu receptor-
mediated protein synthesis3,5–7. Consistent with this theory, the 
eCB-mediated LTD induced at CA1 GABAergic synapses by phar-
macological activation of mGlu5 is similarly enhanced in fmr1 − / −  
mice18. Likewise, in the dorsal striatum of these mutants mGlu5-
mediated eCB activity at GABAergic synapses is increased19. The 
present results, showing that eCB-LTD is abolished in the PFC and 
ventral striatum of fmr1 − / −  mice, are only apparently in opposition 
with those data. Indeed, the notion that different neuron and syn-
apse types adapt differently to the lack of FMRP is supported by a 
recent study showing that mGlu receptor-dependent LTP is reduced 
in the lateral amygdala of fmr1 − / −  mice42. Although we found no 
changes in DGL-α density at GABAergic synapses, 2-AG signal-
ling was suggested to be heterosynaptic between glutamatergic 
and GABAergic synapses43 (that is, 2-AG released from dendritic 
spines might activate CB1 receptors on more distant GABAergic 
terminals). Thus, it is possible that the shifted DGL-α localization 
gradient from the perisynaptic annulus to the spine neck compart-
ment, where GABAergic synapses are often present (for example 
see red arrowhead in Fig. 3n), may underlie the opposite altera-
tions in CB1-dependent regulation of synaptic plasticity between 
these synapses (refs 18,19 and present study). Our findings are in 
line, therefore, with the core prediction of the mGlu receptor the-
ory—namely, the idea that loss of FMRP alters most consequences 
of mGlu5 activation44. On the other hand, the present results reveal 
molecular disparities between excitatory and inhibitory synapses 
of the same brain region, and highlight that distinct forms of LTD 
may also behave differentially in FRAX. While protein synthesis-
dependent LTD is enhanced, presynaptic mGlu2/3-dependent LTD 
is unaffected, and finally the protein synthesis-independent, but 
eCB-mediated, LTD is absent. This palette of synaptic changes might 
underlie the complex neurobehavioural abnormalities observed in 
FRAX patients.
Pharmacological or genetic modulation of mGlu5 signalling nor-
malizes various functional and structural aberrations occurring in 
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Figure 6 | MGL inhibition normalizes behavioural alterations in fmr1 − / −  
mice. Effects of the mGL inhibitor JZL184 on open field (a,b) and elevated 
plus maze (c,d) behaviours. Wild-type and fmr1 − / −  mice received JZL184 
(JZL, 16 mg kg − 1, intraperitoneal) or vehicle (Veh), and were tested 6 h 
after injections. Activity in the open field was measured by counting the 
number of squares crossed (a) and total distance travelled (b). In the 
elevated plus maze test, we measured percentage of open arm entries  
(c) and average time in open per each entry (d). significance was 
determined using two-way analysis of variance with post-hoc student–
newman–Keuls test. ns, not significant; *P < 0.05, and ***P < 0.001 
compared with wild-type-Veh; #P < 0.05, and ##P < 0.01 compared with 
fmr1 − / − -Veh (n = 11 per each group). Error bars represent s.e.m.
ARTICLE 

nATuRE CommunICATIons | DoI: 10.1038/ncomms2045
nATuRE CommunICATIons | 3:1080 | DoI: 10.1038/ncomms2045 | www.nature.com/naturecommunications
© 2012 Macmillan Publishers Limited. All rights reserved.
fmr1 − / −  mice—including hippocampal LTD, immature dendritic 
arbourization and behavioural deficits44. However, this approach is 
unlikely to restore LTD at synapses of the ventral striatum and the 
PFC, where we find mGlu5-dependent eCB production to be down-
regulated. We reasoned therefore that one possible alternative could 
be to restore eCB-mediated plasticity by reducing the degradation of 
its main effector, 2-AG. We used JZL184, an irreversible inhibitor of 
the 2-AG-degrading enzyme MGL33,45,46. This compound proved 
to be effective at restoring eCB-LTD in ventral striatum slices as 
well as correcting two key behavioural changes observed in fmr1 − / −  
mice—elevated motor activity in an open field and decreased aver-
sion to the open arms of an elevated plus maze34. Despite these 
promising findings, the therapeutic potential of JZL184 might be 
limited by its ability to induce CB1 receptor desensitization46. Future 
experimentation will be required to assess whether other classes 
of MGL inhibitors (for example, reversible inhibitors)47 or agents 
that block additional 2-AG-hydrolysing enzymes, such as ABHD629, 
might normalize behaviour in fmr1 − / −  mice without inducing CB1 
desensitization. Supporting the latter possibility, we observed here 
that acute blockade of ABHD6 re-establishes eCB-LTD in ventral 
striatum slices from fmr1 − / −  mice.
In conclusion, our results indicate that FMRP expression is nec-
essary for the correct assembling of the eCB signalosome at gluta-
matergic synapses of the frontal cortex and ventral striatum core, 
and identify this macromolecular complex as a previously unknown 
substrate for FRAX, which might be targeted by therapy.
Methods
Physiology. Animals were treated in compliance with the European Communities 
Council Directive (86/609/EEC) and the United States National Institutes of Health 
Guide for the Care and Use of Laboratory Animals. All animals were housed, 
grouped and acclimated to laboratory conditions for 4 days before experiments 
with 12-h light/dark cycles, and access to food and water ad libitum.
Male fmr1 − / −  mice on a C57BL/6J genetic background48 aged 4 to 12 weeks 
(fmr1 − / − ) were used, with wild-type littermates used as control group. They were 
anesthetized with isoflurane and decapitated according to institutional regulations. 
The brain was sliced (300 µm) in the coronal plane with a vibratome (Integraslice, 
Campden Instruments, Loughborough, UK) in a sucrose-based solution at 4 °C 
(in mM: 87 NaCl, 75 sucrose, 25 glucose, 5 KCl, 21 MgCl2, 0.5 CaCl2 and 1.25 
NaH2PO4). Immediately after cutting, slices were stored at room temperature  
in a low-calcium artificial cerebrospinal fluid (low Ca–ACSF) that contained  
(in mM): 130 NaCl, 11 glucose, 2.5 KCl, 2.4 MgCl2, 1.2 CaCl2, 23 NaHCO3  
and 1.2 NaH2PO4, and was equilibrated with 95% O2/5% CO2 until the time  
of recording.
Whole-cell patch-clamp of visualized medium spiny neurons, PFC pyramidal 
neurons and field potential recordings were made in coronal slices containing  
the ventral striatum or the PFC as previously described8,9,49,50. For more details, 
see Supplementary Methods.
All values are given as mean ± s.e.m. For all experiments, n corresponds to the 
number of animals tested for each condition. Data were analysed using Clampfit 10 
(Molecular Devices, Sunnyvale, USA). Unless otherwise stated, the statistical test 
used was a Mann–Whitney U-test performed with GraphPad Prism (GraphPad 
Software, La Jolla, CA) and significance determined by P < 0.05. The magnitude of 
LTD was calculated by comparing average responses (30–40 min) after induction  
to baseline-averaged responses before induction protocol (increased stimulation 
for 10 min at 10 Hz).
Picrotoxin, THL and anisomycin were from Sigma (St Quentin Fallavier, 
France). 6,7-dinitroquinoxaline-2,3-dione (DNQX), (1R,3R,4R)-3-[2-hydroxy- 
4-(1,1-dimethylheptyl)-phenyl]-4-(3-hydroxypropyl)-cyclohexan-1-ol (CP55940), 
DHPG, AM251, WWL70 and JZL184 were from Tocris (Bristol, UK). Other 
chemicals were of the highest commercial grade available.
Biochemistry. Male fmr1 − / −  mice (FVB.129P2-Fmr1tm1Cgr/J) and wild-type  
control mice (FVB.129P2-Pde6b + Tyrc − ch/AntJ) from Jackson Laboratories  
(Bar Harbor, ME), aged between 6 to 10 weeks, or adult male fmr1 − / −  mice on 
C57BL/6J background (Fmr1 KO2) were used for the biochemical studies. All 
procedures met the National Institutes of Health guidelines for the care and use 
of laboratory animals and were approved by the University of California, Irvine, 
Institutional Animal Care and Use Committee.
All manipulations of brain homogenates were performed at 4 °C51. Synaptone-
urosomes were prepared from whole brains of wild-type or fmr1 − / −  mice. Briefly, 
mice were quickly decapitated, brains were removed and homogenized by 20 
strokes with a glass-Teflon homogenizer in 10 ml of homogenizing buffer (118 mM 
NaCl, 4.7 mM KCl, 1.2 mM MgSO4, 2.5 mM CaCl2, 1.53 mM KH2PO4, 212.7 mM 
glucose, 1 mM DTT, pH7.4, and protease inhibitor) and filtered through a series of 
polypropylene filters (twice through 100 µm and once through 10 µm (BD Filcon). 
Filtrates were spun briefly (1,000 g, 15 min) and the pellets were reconstituted in 
3 ml of homogenizing buffer at a protein concentration of 1 mg ml − 1.
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Figure 7 | Hypothetical role of FMRP in eCB-mediated retrograde transmission. At glutamatergic synapses of wild-type mice (left), mGlu5 receptors 
and DGL-α are linked together in a postsynaptic signalling complex (eCB signalosome), which includes the scaffolding protein Homer. stimulation of 
mGlu5 receptors (mGluR5) by glutamate (green circles) increases DGL-α activity (red arrows), causing a localized rise in 2-AG levels at the perisynapse. 
2-AG (red circles) travels across the synaptic cleft and inhibits glutamate release by stimulating CB1 receptors (CB1R) on nerve endings. We hypothesize 
that FmRP helps target DGL-α to the eCB signalosome, possibly by positioning the DGL-α or Homer message(s) in specific subcellular nanodomain(s). 
In fmr1 − / −  mice (right), the lack of FmRP expression leads to disruption of this spatial organization, loss of localized 2-AG production and, consequently, 
impaired retrograde 2-AG-mediated signalling. AmPAR, AmPA receptors; nmDAR, nmDA receptors; PsD, postsynaptic density. Red arrows indicate 
intracellular signalling pathways triggered by the activation of mGlu5 receptors. molecular pathways that are impaired in fmr1 − / −  mice are shown  
in grey.
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Dissected brain regions were homogenized in methanol (1 ml) containing 
[2H8]-2-AG and N-heptadecanoylethanolamide (Cayman Chemicals, Ann Arbor, 
MI, USA) as internal standards. Protein concentration was determined in the 
homogenate to normalize samples using the bicinchinonic acid protein assay 
(Pierce, Rockford, IL, USA). Lipids were extracted with chloroform (2 ml) and 
water (1 ml), and further fractionated by open-bed silica gel column chromato-
graphy, as previously described52. Lipids were reconstituted in chloroform,  
loaded onto small glass columns packed with Silica Gel G (60-Å 230–400 Mesh 
ASTM; Whatman, Clifton, NJ, USA) and washed with 2 ml of chloroform.  
2-AG were eluted with 1 ml of chloroform/methanol (9:1, vol/vol). Eluates  
were dried under N2 and reconstituted in chloroform/methanol (1:3, 50 µl)  
for liquid chromatography/mass spectrometry (LC/MS) analyses.
An 1100-LC system coupled to a 1946A-MS detector (Agilent Technologies, 
Inc., Palo Alto, CA, USA) equipped with an electrospray ionization interface was 
used to measure anandamide and 2-AG levels in lipid extracts. Lipids were sepa-
rated using a XDB Eclipse C18 column (50×4.6 mm i.d., 1.8 µm, Zorbax), eluted 
with a gradient of methanol in water (from 75 to 85% in 2.5 min, to 90% in 7.5 min, 
to 100% in 14 min and to 75% in 20 min) at a flow rate of 1.0 ml min − 1. Column 
temperature was kept at 40 °C. MS detection was in the positive ionization mode, 
capillary voltage was at 3 kV and fragmentor voltage varied from 120 V. N2  
was used as drying gas at a flow rate of 13 l min − 1 and temperature of 350 °C.  
Nebulizer pressure was set at 60 PSI. Quantifications were conducted using an 
isotope-dilution method52 by monitoring Na +  adducts of the molecular ions 
([M + Na] + ) in the selected ion-monitoring mode. Quantification limits for 2-AG 
was 0.4 pmol. For reverse transcriptase-PCR and quantitative PCR and immuno-
precipitation, detailed procedures are provided in Supplementary Methods.
Results are expressed as the mean ± s.e.m. Statistical significance was evaluated 
using the Student’s t-test.
Animal behaviour. Adult male fmr1 − / −  C57BL/6J mice were used for the animal 
behaviour studies. For open field and elevated plus maze, detailed procedures 
provided in Supplementary Methods53,54.
Anatomy. Experiments were performed according to the guidelines of the insti-
tutional ethical code and the Hungarian Act of Animal Care and Experimentation 
(1998; XXVIII. Section 243/1998). Adult male C57BL/6J mice (three wild-type and 
three fmr1 − / −  mice (8 weeks old) were deeply anesthetized with a mixture of keta-
mine–xylazine (25 mg ml − 1 ketamine, 5 mg ml − 1 xylazine, 0.1% w/w pipolphen in 
H2O; 1 ml per 100 g, intraperitoneal). Animals were then perfused transcardially 
with 0.9% saline for 2 min, followed by 100 ml of fixative containing 4% parafor-
maldehyde and 0.1% glutaraldehyde in 0.1 M phosphate buffer (PB), pH 7.4, for 
20 min. After perfusion, the brain was removed from the skull, cut into blocks, 
post-fixed for 2 h and washed in PB. The blocks containing the ventral striatum 
were sliced into 50-µm-thick coronal sections of the brain with a Leica VTS-1000 
vibratome (Vibratome, St Louis, MO, USA).
After slicing and extensive washing in 0.1 M PB, the sections were incubated 
in 10% sucrose for 15 min and 30% sucrose overnight, followed by freeze thawing 
over liquid nitrogen four times. Subsequently, all washing steps and dilutions of 
the antibodies were performed in 0.05 M Tris-buffered saline (TBS), pH 7.4. After 
extensive washing in TBS, the sections were blocked in 5% normal goat serum for 
45 min and then incubated in rabbit anti-DGL-α (1:3,000, ‘INT’;13) or rabbit anti-
mGlu5 (1:1,000, AB5675, Millipore, Billerica, MA, USA) for a minimum of 48 h at 
4 °C. In the immunoperoxidase staining procedure, after primary antibody incuba-
tions, the sections were treated with biotinylated goat anti-rabbit IgG (1:400, Vector 
Laboratories) for 2 h and after three washes in TBS, with avidin biotinylated– 
horseradish peroxidase complex (1:500; Elite ABC; Vector Laboratories) for 1.5 h. 
After extensive washing, the immunoperoxidase reaction was developed using 
3,3′-diaminobenzidine as the chromogen. In the immunogold staining procedure, 
after the primary antibody incubation, the sections were washed extensively in 
TBS before incubation in 0.8 nm gold-conjugated goat anti-rabbit secondary 
antibody (1:50; AURION, Wageningen, The Netherlands), overnight at 4 °C. Then 
sections were silver intensified using the silver enhancement system R-GENT 
SE-EM according to the kit protocol (AURION). After development of both types 
of immunolabelling, the sections were treated with osmium tetroxide (0.5% for 
immunogold labelling, 1% for immunoperoxidase reaction) in 0.1M PB for 20 min 
(at 4 °C for immunogold labelling) and dehydrated in an ascending series of ethanol 
and acetonitrile, before being embedded in Durcupan (ACM, Fluka, Buchs,  
Switzerland). During dehydration, sections were treated with 1% uranyl acetate in 
70% ethanol for 15 min (at 4 °C for immunogold labelling). Immunoperoxidase-
labelled sections were imaged with a Nikon Eclipse 80i microscope (Nikon Instru-
ments Europe B.V., Amsterdam, The Netherlands) and light micrographs were  
captured with a DS-Fi1 digital camera (Nikon Instruments Europe B.V., Amsterdam, 
The Netherlands). For electron microscopy analysis, areas of interest in the ventral 
striatum core were removed from Durcupan-embedded sections, then re-embedded 
and re-sectioned. Ultrathin (60 nm) sections were collected on Formvar-coated 
single-slot grids and stained with lead citrate. Electron micrographs were taken at 
×40,000 magnifications with a Hitachi 7100 electron microscope (Tokyo, Japan).
Quantitative analysis of the distribution of DGL- and mGlu5 in dendritic spines: 
see Supplementary Methods. 
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